Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Polyneuropathies 1Polycystic Ovary Syndrome 1Neoplasms 1Multiple Myeloma 1Mucositis 1Mouth Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Hematologic Neoplasms 1Glioma 1Frailty 1Fanconi Anemia 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Quercetin × Clear all
NCT06940297 2026-02-06

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 2 Recruiting
44 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡